consensus for FY 23 revenue is $92.12M.. Sight Sciences updates revenue guidance expectations for the full year 2023 to $80M to $82M which represents growth of approximately 12% to 15% compared to 2022, from the prior revenue guidance range of $89Mto $94M. The Company expects the guidance for the third quarter of 2023 is a reasonable expectation for quarterly revenue run rate until customers gain more visibility into longer term Medicare coverage for OMNI. Should OMNI procedures remain covered for Medicare beneficiaries after the final LCDs are published, the Company would expect a return to historical growth rates. The Company plans to discuss complete third quarter 2023 financial results in early November 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences (NASDAQ:SGHT) Tanks 31% After Slashing Outlook
- Sight Sciences Appoints Matt Link as Chief Commercial Officer
- Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023
- Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
- Sight Sciences downgraded to Equal Weight from Overweight at Morgan Stanley